Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.41 |
| ▸ | TNF | P01375 | 4/20 | 0.39 |
| ▸ | ACSS2 | Q9NR19 | 5/20 | 0.37 |
| ▸ | CNR1 | P21554 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | MET | P08581 | 1/20 | 0.34 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | PTGES | O14684 | 2/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30647654 | 1.00 | DYRK1B (0.41) | DYRK1BTNFACSS2CNR1CYP3A4 | |
| SCHEMBL30647611 | 0.82 | LMNA (0.46) | ACSS2CYP3A4TSHRCYP2C19KDM4E | |
| SCHEMBL32684875 | 0.80 | KDM4E (0.41) | ACSS2METKDM4E | |
| SCHEMBL31510539 | 0.80 | KDM4E (0.41) | ACSS2METKDM4E | |
| SCHEMBL15043734 | 0.74 | RIPK2 (0.47) | DYRK1BCNR1CYP2C19KDM4EMAPT | |
| SCHEMBL30050271 | 0.71 | CCNC (0.48) | DYRK1BCNR1KDM4E | |
| SCHEMBL317086 | 0.71 | CCNC (0.48) | DYRK1BCNR1KDM4E | |
| SCHEMBL23126660 | 0.67 | ACSS2 (0.36) | ACSS2CYP3A4TSHRCYP2C19GABRA1 | |
| SCHEMBL29691695 | 0.66 | CCNC (0.49) | DYRK1BCYP2C19PIK3CAKDM4EMAPT | |
| SCHEMBL265444 | 0.66 | CCNC (0.49) | DYRK1BCYP2C19PIK3CAKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070899-A1 | N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-QUINOLINE-4-CARBOXAMIDES | ASTRAZENECA AB (SE) | 2026-03-12 | — | — | US | disclosed |
| EP-4543878-A1 | N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)- QUINOLINE-4-CARBOXAMIDES | Astrazeneca AB (SE) | 2025-04-30 | — | — | EP | disclosed |
| CN-119562951-A | N- (2- (4-cyanothiazolidin-3-yl) -2-oxoethyl) -quinoline-4-carboxamide | 阿斯利康(瑞典)有限公司 | 2025-03-04 | — | — | CN | disclosed |
| WO-2023247489-A1 | N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)- QUINOLINE-4-CARBOXAMIDES | ASTRAZENECA AB (SE) | 2023-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070899-A1 | N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-QUINOLINE-4-CARBOXAMIDES | FAP, CTRL, CTSC | DYRK1B 4554/4885TNF 2108/4885ACSS2 3026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.